[A13-14] Addendum to Commission A12-16 Saxagliptin/metformin
|Commission:||Commission awarded on 2013-03-27 by the Federal Joint Committee (G-BA)|
|Current document:||Addendum to Commission A12-16 (Saxagliptin/metformin) Further documents|
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|Contact address:||to the contact form|
Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
|2013-05-02||Addendum to Commission A12-16 (Saxagliptin/metformin)||443 kB|
Federal Joint Committee (G-BA)
2013-05-02 A G-BA decision was published.